Skip to main content
SpringerLink
Log in

Paraneoplastic Neuromuscular Disorders

  • Chapter
  • First Online:
Neuromuscular Disorders in Clinical Practice

Abstract

Paraneoplastic neurologic and neuromuscular disorders are usually immune mediated and often associated with specific anti-neuronal antibodies. This chapter will focus on those paraneoplastic disorders that predominantly produce neuromuscular dysfunction and which are likely to be encountered in clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 449.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75:1135–40.

    Article  CAS  PubMed  Google Scholar 

  2. Vernino S, O’Neill BP, Marks RS, O’Fallon JR, Kimmel DW. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro Oncol. 2004;6:55–62.

    Article  PubMed  Google Scholar 

  3. Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore). 1992;71:59–72.

    CAS  Google Scholar 

  4. Oki Y, Koike H, Iijima M, et al. Ataxic vs painful form of paraneoplastic neuropathy. Neurology. 2007;69:564–72.

    Article  CAS  PubMed  Google Scholar 

  5. Kuntzer T, Antoine JC, Steck AJ. Clinical features and pathophysiological basis of sensory neuronopathies (ganglionopathies). Muscle Nerve. 2004;30:255–68.

    Article  PubMed  Google Scholar 

  6. Graus F, Keime-Guibert F, Rene R, et al. Anti-Hu-associated ­paraneoplastic encephalomyelitis: analysis of 200 patients. Brain. 2001;124:1138–48.

    Article  CAS  PubMed  Google Scholar 

  7. Eggers C, Hagel C, Pfeiffer G. Anti-Hu-associated paraneoplastic sensory neuropathy with peripheral nerve demyelination and ­microvasculitis. J Neurol Sci. 1998;155:178–81.

    Article  CAS  PubMed  Google Scholar 

  8. Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: neurological ­symptoms, immunological findings, and tumor association in 50 patients. Brain. 2000;123:1481–94.

    Article  PubMed  Google Scholar 

  9. Fujimoto S, Kumamoto T, Ito T, Sannomiya K, Inuzuka T, Tsuda T. A clinicopathological study of a patient with anti-Hu-associated paraneoplastic sensory neuronopathy with multiple cranial nerve palsies. Clin Neurol Neurosurg. 2002;104:98–102.

    Article  PubMed  Google Scholar 

  10. Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and ­oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology. 1998;50:652–7.

    Article  CAS  PubMed  Google Scholar 

  11. Llado A, Carpentier AF, Honnorat J, et al. Hu-antibody-positive patients with or without cancer have similar clinical profiles. J Neurol Neurosurg Psychiatry. 2006;77:996–7.

    Article  CAS  PubMed  Google Scholar 

  12. Honnorat J, Cartalat-Carel S, Ricard D, et al. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry. 2009;80:412–6.

    Article  CAS  PubMed  Google Scholar 

  13. Yu Z, Kryzer TJ, Griesmann GE, Kim KK, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma related autoimmunity. Ann Neurol. 2001;49:146–54.

    Article  CAS  PubMed  Google Scholar 

  14. Camdessanche JP, Antoine JC, Honnorat J, et al. Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients. Brain. 2002;125:166–75.

    Article  PubMed  Google Scholar 

  15. Oh SJ, Gurtekin Y, Dropcho EJ, King P, Claussen GC. Anti-Hu antibody neuropathy: a clinical, electrophysiological, and pathological study. Clin Neurophysiol. 2005;116:28–34.

    Article  PubMed  Google Scholar 

  16. Sillevis SP, Grefkens J, De Leeuw B, et al. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol. 2002;249:745–53.

    Article  Google Scholar 

  17. Camdessanche JP, Jousserand G, Ferraud K, et al. The pattern and diagnostic criteria of sensory neuronopathy: a case–control study. Brain. 2009;132:1723–33.

    Article  PubMed  Google Scholar 

  18. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol. 2006;24:1633–42.

    Article  CAS  PubMed  Google Scholar 

  19. Krishnan AV, Goldstein D, Friedlander M, Kiernan MC. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve. 2005;32:51–60.

    Article  CAS  PubMed  Google Scholar 

  20. Plasmati R, Pastorelli F, Cavo M, et al. Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology. 2007;69:573–81.

    Article  CAS  PubMed  Google Scholar 

  21. Willison HJ, O’Leary CP, Veitch J, et al. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain. 2001;124:1968–77.

    Article  CAS  PubMed  Google Scholar 

  22. Sanvito L, Rajabally YA. Optic neuropathy associated with CANOMAD: description of 2 cases. Muscle Nerve. 2011;44:451–5.

    PubMed  Google Scholar 

  23. Chio A, Brignolio F, Meineri P, Rosso MG, Tribolo A, Schiffer D. Motor neuron disease and malignancies: results of a population-based study. J Neurol. 1988;235:374–5.

    Article  CAS  PubMed  Google Scholar 

  24. Kurtzke JF, Beebe GW. Epidemiology of amyotrophic lateral sclerosis: 1. A case–control comparison based on ALS deaths. Neurology. 1980;30:453–62.

    Article  CAS  PubMed  Google Scholar 

  25. Chio A, Calvo A, Moglia C, et al. May ALS phenotype be considered a part of the disease spectrum of paraneoplastic diseases? Amyotroph Lateral Scler. 2011;12 suppl 1:24.

    Google Scholar 

  26. Evans BK, Fagan C, Arnold T, Dropcho EJ, Oh SJ. Paraneoplastic motor neuron disease and renal cell carcinoma: improvement after nephrectomy. Neurology. 1990;40:960–2.

    Article  CAS  PubMed  Google Scholar 

  27. Forman D, Rae-Grant AD, Matchett SC, Cowen JS. A reversible cause of hypercapnic respiratory failure: lower motor neuronopathy associated with renal cell carcinoma. Chest. 1999;115:899–901.

    Article  CAS  PubMed  Google Scholar 

  28. Ferracci F, Fassetta G, Butler MH, Floyd S, Solimena M, De Camilli P. A novel antineuronal antibody in a motor neuron syndrome associated with breast cancer. Neurology. 1999;53:852–5.

    Article  CAS  PubMed  Google Scholar 

  29. Forsyth PA, Dalmau J, Graus F, Cwik V, Rosenblum MK, Posner JB. Motor neuron syndromes in cancer patients. Ann Neurol. 1997;41:722–30.

    Article  CAS  PubMed  Google Scholar 

  30. Carnevale V, Minisola S, Romagnoli E, et al. Concurrent improvement of neuromuscular and skeletal involvement following surgery for primary hyperparathyroidism. J Neurol. 1992;239:57.

    Article  CAS  PubMed  Google Scholar 

  31. Thomas P, Lebrun C. Progressive spastic paraparesis revealing ­primary hyperparathyroidism. Neurology. 1994;44:178–9.

    Article  CAS  PubMed  Google Scholar 

  32. Jackson CE, Amato AA, Bryan WW, Wolfe GI, Sakhaee K, Barohn RJ. Primary hyperparathyroidism and ALS: is there a relation? Neurology. 1998;50:1795–9.

    Article  CAS  PubMed  Google Scholar 

  33. Rison RA, Beydoun SR. Amyotrophic lateral sclerosis-motor ­neuron disease, monoclonal gammopathy, hyperparathyroidism, and B12 deficiency: case report and review of the literature. J Med Case Reports. 2010;4:298.

    Article  Google Scholar 

  34. Carvalho AA, Vieira A, Simplicio H, Fugygara S, Carvalho SM, Rigueiro MP. Primary hyperparathyroidism simulating motor ­neuron disease: case report. Arq Neuropsiquiatr. 2005;63:160–2.

    Article  PubMed  Google Scholar 

  35. Barker RA, Revesz T, Thom M, Marsden CD, Brown P. Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry. 1998;65:633–40.

    Article  CAS  PubMed  Google Scholar 

  36. Saiz A, Blanco Y, Sabater L, et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain. 2008;131:2553–63.

    Article  PubMed  Google Scholar 

  37. Agarwal PA, Ichaporia NR. Glutamic acid decarboxylase antibody-positive paraneoplastic stiff limb syndrome associated with carcinoma of the breast. Neurol India. 2010;58:449–51.

    Article  PubMed  Google Scholar 

  38. Schiff D, Dalmau J, Myers DJ. Anti-GAD antibody positive ­stiff-limb syndrome in multiple myeloma. J Neurooncol. 2003;65:173–5.

    Article  PubMed  Google Scholar 

  39. Hagiwara H, Enomoto-Nakatani S, Sakai K, Ugawa Y, Kusunoki S, Kanazawa I. Stiff-person syndrome associated with invasive ­thymoma: a case report. J Neurol Sci. 2001;193:59–62.

    Article  CAS  PubMed  Google Scholar 

  40. Pittock SJ, Lucchinetti CF, Parisi JE, et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol. 2005;58:96–107.

    Article  PubMed  Google Scholar 

  41. Murinson BB, Guarnaccia JB. Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease. Neurology. 2008;71:1955–8.

    Article  CAS  PubMed  Google Scholar 

  42. Ruegg SJ, Steck AJ, Fuhr P. Levetiracetam improves paroxysmal symptoms in a patient with stiff-person syndrome. Neurology. 2004;62:338.

    Article  PubMed  Google Scholar 

  43. Holmoy T. Long-term effect of gabapentin in stiff limb syndrome: a case report. Eur Neurol. 2007;58:251–2.

    Article  PubMed  Google Scholar 

  44. Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B. ­High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med. 2001;345:1870–6.

    Article  CAS  PubMed  Google Scholar 

  45. Schmierer K, Valdueza JM, Bender A, et al. Atypical stiff-person syndrome with spinal MRI findings, amphiphysin autoantibodies, and immunosuppression. Neurology. 1998;51:250–2.

    Article  CAS  PubMed  Google Scholar 

  46. Flanagan EP, McKeon A, Lennon VA, et al. Paraneoplastic isolated myelopathy: clinical course and neuroimaging Clues. Neurology. 2011;76:2089–95.

    Article  CAS  PubMed  Google Scholar 

  47. Julien J, Vital C, Aupy G, Lagueny A, Darriet D, Brechenmacher C. Guillain-Barre syndrome and Hodgkin’s disease. Ultrastructural study of a peripheral nerve. J Neurol Sci. 1980;45:23–7.

    Article  CAS  PubMed  Google Scholar 

  48. Vigliani MC, Magistrello M, Polo P, Mutani R, Chio A. Risk of cancer in patients with Guillain-Barre syndrome (GBS). A population-based study. J Neurol. 2004;251:321–6.

    Article  PubMed  Google Scholar 

  49. Nokura K, Nagamatsu M, Inagaki T, et al. Acute motor and sensory neuronopathy associated with small-cell lung cancer: a clinicopathological study. Neuropathology. 2006;26:329–37.

    Article  PubMed  Google Scholar 

  50. Croft PB, Urich H, Wilkinson M. Peripheral neuropathy of sensorimotor type associated with malignant disease. Brain. 1967;90:31–66.

    Article  CAS  PubMed  Google Scholar 

  51. Samarasekera S, Rajabally YA. Demyelinating neuropathy with anti-CRMP5 antibodies predating diagnosis of breast carcinoma: favorable outcome after cancer therapy. Muscle Nerve. 2011;43:764–6.

    Article  CAS  PubMed  Google Scholar 

  52. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton III LJ. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc. 2004;79:859–66.

    Article  PubMed  Google Scholar 

  53. Rajabally YA. Neuropathy and paraproteins: review of a complex association. Eur J Neurol. 2011;18:1291–8.

    Article  CAS  PubMed  Google Scholar 

  54. Nobile-Orazio E, Manfredini E, Carpo M, et al. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol. 1994;36:416–24.

    Article  CAS  PubMed  Google Scholar 

  55. Nobile-Orazio E, Hays AP, Latov N, et al. Specificity of mouse and human monoclonal antibodies to myelin-associated glycoprotein. Neurology. 1984;34:1336–42.

    Article  CAS  PubMed  Google Scholar 

  56. Steck AJ, Stalder AK, Renaud S. Anti-myelin-associated glycoprotein neuropathy. Curr Opin Neurol. 2006;19:458–63.

    Article  CAS  PubMed  Google Scholar 

  57. Steck AJ, Murray N, Dellagi K, Brouet JC, Seligmann M. Peripheral neuropathy associated with monoclonal IgM autoantibody. Ann Neurol. 1987;22:764–7.

    Article  CAS  PubMed  Google Scholar 

  58. Nobile-Orazio E, Meucci N, Baldini L, Di TA, Scarlato G. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain. 2000;123:710–7.

    Article  PubMed  Google Scholar 

  59. Yeung KB, Thomas PK, King RH, et al. The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings. J Neurol. 1991;238:383–91.

    Article  CAS  PubMed  Google Scholar 

  60. Larue S, Bombelli F, Viala K, et al. Non-anti-MAG DADS ­neuropathy as a variant of CIDP: clinical, electrophysiological, laboratory features and response to treatment in 10 cases. Eur J Neurol. 2011;18:899–905.

    Article  CAS  PubMed  Google Scholar 

  61. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol. 2003;30:110–5.

    Article  PubMed  Google Scholar 

  62. Gertz MA. Waldenstrom macroglobulinemia: a review of therapy. Am J Hematol. 2005;79:147–57.

    Article  CAS  PubMed  Google Scholar 

  63. Dimopoulos MA, Alexanian R. Waldenstrom’s macroglobulinemia. Blood. 1994;83:1452–9.

    CAS  PubMed  Google Scholar 

  64. Levine T, Pestronk A, Florence J, et al. Peripheral neuropathies in Waldenstrom’s macroglobulinaemia. J Neurol Neurosurg Psychiatry. 2006;77:224–8.

    Article  CAS  PubMed  Google Scholar 

  65. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR. Amyloidosis: diagnosis and management. Clin Lymphoma Myeloma. 2005;6:208–19.

    Article  CAS  PubMed  Google Scholar 

  66. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve. 2007;36:411–23.

    Article  CAS  PubMed  Google Scholar 

  67. Kelly Jr JJ, Kyle RA, O’Brien PC, Dyck PJ. The natural history of peripheral neuropathy in primary systemic amyloidosis. Ann Neurol. 1979;6:1–7.

    Article  PubMed  Google Scholar 

  68. Tracy JA, Dyck PJ, Dyck PJ. Primary amyloidosis presenting as upper limb multiple mononeuropathies. Muscle Nerve. 2010;41:710–5.

    Article  PubMed  Google Scholar 

  69. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997;336:1202–7.

    Article  CAS  PubMed  Google Scholar 

  70. Gertz MA, Lacy MQ, Dispenzieri A, et al. Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. Bone Marrow Transplant. 2011;46:970–5.

    Article  CAS  PubMed  Google Scholar 

  71. Sonneveld P, Jongen JL. Dealing with neuropathy in plasma-cell dyscrasias. Hematology Am Soc Hematol Educ Program. 2010;2010:423–30.

    Article  PubMed  Google Scholar 

  72. Miralles GD, O’Fallon JR, Talley NJ. Plasma-cell dyscrasia with polyneuropathy. The spectrum of POEMS syndrome. N Engl J Med. 1992;327:1919–23.

    Article  CAS  PubMed  Google Scholar 

  73. Sung JY, Kuwabara S, Ogawara K, Kanai K, Hattori T. Patterns of nerve conduction abnormalities in POEMS syndrome. Muscle Nerve. 2002;26:189–93.

    Article  PubMed  Google Scholar 

  74. Vital C, Vital A, Ferrer X, et al. Crow-Fukase (POEMS) syndrome: a study of peripheral nerve biopsy in five new cases. J Peripher Nerv Syst. 2003;8:136–44.

    Article  PubMed  Google Scholar 

  75. Kuwabara S, Dispenzieri A, Arimura K, Misawa S. Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. Cochrane Database Syst Rev. 2008;4:CD006828.

    Google Scholar 

  76. Castleman B, Towne VW. Case records of the Massachusetts General Hospital: case no. 40231. N Engl J Med. 1954;250:1001–5.

    Article  CAS  PubMed  Google Scholar 

  77. Powles T, Stebbing J, Bazeos A, et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated ­multicentric Castleman’s disease. Ann Oncol. 2009;20:775–9.

    Article  CAS  PubMed  Google Scholar 

  78. Donaghy M, Hall P, Gawler J, et al. Peripheral neuropathy associated with Castleman’s disease. J Neurol Sci. 1989;89:253–67.

    Article  CAS  PubMed  Google Scholar 

  79. Zivkovic SA, Ascherman D, Lacomis D. Vasculitic neuropathy – electrodiagnostic findings and association with malignancies. Acta Neurol Scand. 2007;115:432–6.

    Article  CAS  PubMed  Google Scholar 

  80. Johnson PC, Rolak LA, Hamilton RH, Laguna JF. Paraneoplastic vasculitis of nerve: a remote effect of cancer. Ann Neurol. 1979;5:437–44.

    Article  CAS  PubMed  Google Scholar 

  81. Younger DS, Dalmau J, Inghirami G, Sherman WH, Hays AP. Anti-Hu-associated peripheral nerve and muscle microvasculitis. Neurology. 1994;44:181–3.

    Article  CAS  PubMed  Google Scholar 

  82. Martin AC, Friedlander M, Kiernan MC. Paraneoplastic mononeuritis multiplex in non-small-cell lung carcinoma. J Clin Neurosci. 2006;13:595–8.

    Article  PubMed  Google Scholar 

  83. Oh SJ, Slaughter R, Harrell L. Paraneoplastic vasculitic neuropathy: a treatable neuropathy. Muscle Nerve. 1991;14:152–6.

    Article  CAS  PubMed  Google Scholar 

  84. Blumenthal D, Schochet Jr S, Gutmann L, Ellis B, Jaynes M, Dalmau J. Small-cell carcinoma of the lung presenting with paraneoplastic peripheral nerve microvasculitis and optic neuropathy. Muscle Nerve. 1998;21:1358–9.

    Article  CAS  PubMed  Google Scholar 

  85. Tahmoush AJ, Alonso RJ, Tahmoush GP, Heiman-Patterson TD. Cramp-fasciculation syndrome: a treatable hyperexcitable peripheral nerve disorder. Neurology. 1991;41:1021–4.

    Article  CAS  PubMed  Google Scholar 

  86. Hart IK, Maddison P, Newsom-Davis J, Vincent A, Mills KR. Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain. 2002;125:1887–95.

    Article  PubMed  Google Scholar 

  87. Isaacs H. A syndrome of continuous muscle-fibre activity. J Neurol Neurosurg Psychiatry. 1961;24:319–25.

    Article  CAS  PubMed  Google Scholar 

  88. Morvan A. De la chorée fibrillaire. Gaz Hebd Mèd Chir. 1890;27:173–200.

    Google Scholar 

  89. Rubio-Agusti I, Perez-Miralles F, Sevilla T, et al. Peripheral nerve hyperexcitability: a clinical and immunologic study of 38 patients. Neurology. 2011;76:172–8.

    Article  CAS  PubMed  Google Scholar 

  90. Vernino S, Lennon VA. Ion channel and striational antibodies define a continuum of autoimmune neuromuscular hyperexcitability. Muscle Nerve. 2002;26:702–7.

    Article  CAS  PubMed  Google Scholar 

  91. Lancaster E, Huijbers MG, Bar V, et al. Investigations of Caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol. 2011;69:303–11.

    Article  CAS  PubMed  Google Scholar 

  92. Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain. 2010;133:2734–48.

    Article  PubMed  Google Scholar 

  93. Maddison P, Mills KR, Newsom-Davis J. Clinical electrophysiological characterization of the acquired neuromyotonia phenotype of autoimmune peripheral nerve hyperexcitability. Muscle Nerve. 2006;33:801–8.

    Article  PubMed  Google Scholar 

  94. Lee EK, Maselli RA, Ellis WG, Agius MA. Morvan’s fibrillary chorea: a paraneoplastic manifestation of thymoma. J Neurol Neurosurg Psychiatry. 1998;65:857–62.

    Article  CAS  PubMed  Google Scholar 

  95. Bednarlk J, Kadanka Z. Volitional and stimulation induced neuromyotonic discharges: unusual electrophysiological pattern in acquired neuromyotonia. J Neurol Neurosurg Psychiatry. 2001;70:406–7.

    Article  CAS  PubMed  Google Scholar 

  96. Humphrey JG, Hill ME, Gordon AS, Kalow W. Myotonia associated with small cell carcinoma of the lung. Arch Neurol. 1976;33:375–6.

    Article  CAS  PubMed  Google Scholar 

  97. Sanders DB, Massey JM. Clinical features of myasthenia gravis. Handb Clin Neurol. 2008;91:229–52.

    Article  PubMed  Google Scholar 

  98. Husain AM, Massey JM, Howard JF, Sanders DB. Acetylcholine receptor antibody measurements in acquired myasthenia gravis. Diagnostic sensitivity and predictive value for thymoma. Ann N Y Acad Sci. 1998;841:471–4.

    Article  CAS  PubMed  Google Scholar 

  99. Howard Jr JF, Sanders DB, Massey JM. The electrodiagnosis of myasthenia gravis and the Lambert-Eaton myasthenic syndrome. Neurol Clin. 1994;12:305–30.

    PubMed  Google Scholar 

  100. Meriggioli MN, Sanders DB. Myasthenia gravis: diagnosis. Semin Neurol. 2004;24:31–9.

    Article  PubMed  Google Scholar 

  101. Bril V, Kojic J, Dhanani A. The long-term clinical outcome of myasthenia gravis in patients with thymoma. Neurology. 1998;51:1198–200.

    Article  CAS  PubMed  Google Scholar 

  102. Tormoehlen LM, Pascuzzi RM. Thymoma, myasthenia gravis, and other paraneoplastic syndromes. Hematol Oncol Clin North Am. 2008;22:509–26.

    Article  PubMed  Google Scholar 

  103. Maggi L, Andreetta F, Antozzi C, et al. Thymoma-associated myasthenia gravis: outcome, clinical and pathological correlations in 197 patients on a 20-year experience. J Neuroimmunol. 2008;201–202:237–44.

    Article  PubMed  CAS  Google Scholar 

  104. Suzuki S, Utsugisawa K, Nagane Y, Suzuki N. Three types of striational antibodies in myasthenia gravis. Autoimmune Disord. 2011;2011:740583.

    Google Scholar 

  105. Romi F, Gilhus NE, Aarli JA. Myasthenia gravis: clinical, immunological, and therapeutic advances. Acta Neurol Scand. 2005;111:134–41.

    Article  CAS  PubMed  Google Scholar 

  106. Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve. 2011;44:36–40.

    Article  PubMed  Google Scholar 

  107. Zahid I, Sharif S, Routledge T, Scarci M. Video-assisted ­thoracoscopic surgery or transsternal thymectomy in the treatment of myasthenia gravis? Interact Cardiovasc Thorac Surg. 2011;12:40–6.

    Article  PubMed  Google Scholar 

  108. Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest. 2006;116:2843–54.

    Article  CAS  PubMed  Google Scholar 

  109. Maggi L, Mantegazza R. Treatment of myasthenia gravis: focus on pyridostigmine. Clin Drug Investig. 2011;31:691–701.

    Article  CAS  PubMed  Google Scholar 

  110. O’Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain. 1988;111:577–96.

    Article  PubMed  Google Scholar 

  111. Hatanaka Y, Oh SJ. Ten-second exercise is superior to 30-s exercise for post-exercise facilitation in diagnosing Lambert-Eaton myasthenic syndrome. Muscle Nerve. 2008;37:572–5.

    Article  PubMed  Google Scholar 

  112. Titulaer MJ, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms. Ann N Y Acad Sci. 2008;1132:129–34.

    Article  PubMed  Google Scholar 

  113. Argov Z, Shapira Y, Averbuch-Heller L, Wirguin I. Lambert-Eaton myasthenic syndrome (LEMS) in association with lymphoproliferative disorders. Muscle Nerve. 1995;18:715–9.

    Article  CAS  PubMed  Google Scholar 

  114. Morimoto M, Osaki T, Nagara Y, Kodate M, Motomura M, Murai H. Thymoma with Lambert-Eaton myasthenic syndrome. Ann Thorac Surg. 2010;89:2001–3.

    Article  PubMed  Google Scholar 

  115. Wirtz PW, Smallegange TM, Wintzen AR, Verschuuren JJ. Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases. Clin Neurol Neurosurg. 2002;104:359–63.

    Article  PubMed  Google Scholar 

  116. Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol. 2011;18:19-e3.

    Article  PubMed  Google Scholar 

  117. Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med. 1995;332:1467–74.

    Article  CAS  PubMed  Google Scholar 

  118. Motomura M, Lang B, Johnston I, Palace J, Vincent A, ­Newsom-Davis J. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton ­myasthenic syndrome. J Neurol Sci. 1997;147:35–42.

    Article  CAS  PubMed  Google Scholar 

  119. Sabater L, Titulaer M, Saiz A, Verschuuren J, Gure AO, Graus F. SOX1 antibodies are markers of paraneoplastic Lambert Eaton myasthenic syndrome. J Clin Oncol. 2007;27:4260–7.

    Google Scholar 

  120. Titulaer MJ, Maddison P, Sont JK, et al. Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol. 2011;29:902–8.

    Article  PubMed  Google Scholar 

  121. Keogh M, Sedehizadeh S, Maddison P. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev 2011;(2):CD003279.

    Google Scholar 

  122. Sanders DB, Massey JM, Sanders LL, Edwards LJ. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic ­syndrome. Neurology. 2000;54:603–7.

    Article  CAS  PubMed  Google Scholar 

  123. Wirtz PW, Verschuuren JJ, van Dijk JG, et al. Efficacy of 3,4-­diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther. 2009;86:44–8.

    Article  CAS  PubMed  Google Scholar 

  124. Lindquist S, Stangel M. Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine. Neuropsychiatr Dis Treat. 2011;7:341–9.

    CAS  PubMed  Google Scholar 

  125. Newsom-Davis J, Murray NM. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic ­syndrome. Neurology. 1984;34:480–5.

    Article  CAS  PubMed  Google Scholar 

  126. Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology. 1998;50:1778–83.

    Article  CAS  PubMed  Google Scholar 

  127. Tim RW, Massey JM, Sanders DB. Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment. Neurology. 2000;54:2176–8.

    Article  CAS  PubMed  Google Scholar 

  128. Bain PG, Motomura M, Newsom-Davis J, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology. 1996;47:678–83.

    Article  CAS  PubMed  Google Scholar 

  129. Maddison P, McConville J, Farrugia ME, et al. The use of ­rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 2011;82:671–3.

    Article  PubMed  Google Scholar 

  130. Pellkofer HL, Voltz R, Kuempfel T. Favorable response to ­rituximab in a patient with anti-VGCC-positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunction. Muscle Nerve. 2009;40:305–8.

    Article  CAS  PubMed  Google Scholar 

  131. Hochberg MC, Feldman D, Stevens MB, Arnett FC, Reichlin M. Antibody to Jo-1 polymyositis/dermatomyositis: association with interstitial pulmonary disease. J Rheumatol. 1984;11:663–5.

    CAS  PubMed  Google Scholar 

  132. Dalakas MC. Immunopathogenesis of inflammatory myopathies. Ann Neurol. 1995;37:S74–5.

    Article  PubMed  Google Scholar 

  133. Smith B. Skeletal muscle necrosis associated with cainoma. J Pathol. 1969;97:207–10.

    Article  CAS  PubMed  Google Scholar 

  134. Bronner IM, Hoogendijk JE, Wintzen AR, et al. Necrotising ­myopathy, an unusual presentation of a steroid-responsive ­myopathy. J Neurol. 2003;250:480–5.

    Article  CAS  PubMed  Google Scholar 

  135. Urich H, Wilkinson M. Necrosis of muscle with carcinoma: myositis or myopathy? J Neurol Neurosurg Psychiatry. 1970;33:398–407.

    Article  CAS  PubMed  Google Scholar 

  136. Levin MI, Mozaffar T, Al-Lozi MT, Pestronk A. Paraneoplastic necrotizing myopathy: clinical and pathological features. Neurology. 1998;50:764–7.

    Article  CAS  PubMed  Google Scholar 

  137. Galani E, Bonakis A, Christodoulou C, Klouvas G, Drougou A, Skarlos D. Can cetuximab affect paraneoplastic myopathy? J Neurooncol. 2009;93:437–8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University of Arkansas for Medical Sciences, 4301 W. Markham, #500, Little Rock, AR, 72205, USA

    Betul Gundogdu MD & Stacy A. Rudnicki MD

  2. Department of Neurology, Institute of Biomedical Investigations (IDIBAPS), Clinic Hospital, Villarroel, 170, Barcelona, 08036, Spain

    Myrna R. Rosenfeld MD, PhD

Authors
  1. Betul Gundogdu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Myrna R. Rosenfeld MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stacy A. Rudnicki MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stacy A. Rudnicki MD .

Editor information

Editors and Affiliations

  1. School of Medicine Department of Neurology, University Hospitals Case Medical Center Case Western Reserve University, Cleveland, Ohio, USA

    Bashar Katirji

  2. Department of Neurology, George Washington University, Washington, District of Columbia, USA

    Henry J. Kaminski

  3. University School of Medicine Department of Neurology, Louis Stokes Cleveland VA Medical Center Case Western Reserve, Cleveland, Ohio, USA

    Robert L. Ruff

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Gundogdu, B., Rosenfeld, M.R., Rudnicki, S.A. (2014). Paraneoplastic Neuromuscular Disorders. In: Katirji, B., Kaminski, H., Ruff, R. (eds) Neuromuscular Disorders in Clinical Practice. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6567-6_75

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-6567-6_75

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-6566-9

  • Online ISBN: 978-1-4614-6567-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation